Metastatic HER2-positive Breast Cancer Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Ambrx, Zymeworks, Jazz Pharma, Roche, Criterium, Seagen, Sichuan

Posted on
by

Metastatic HER2-positive Breast Cancer Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Ambrx, Zymeworks, Jazz Pharma, Roche, Criterium, Seagen, Sichuan
The Key Metastatic HER2-positive Breast Cancer Companies in the market include – MacroGenics, TerSera Therapeutics, Roche, Chugai, Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others.

 

DelveInsight’s “Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Metastatic HER2-positive Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HER2-positive Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Metastatic HER2-positive Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market

 

Some of the key facts of the Metastatic HER2-positive Breast Cancer Market Report:

  • The metastatic HER2-positive breast cancer market size was estimated at nearly USD 2.9 billion in 2025 and is anticipated to expand at a CAGR of approximately 8.3% during the forecast period from 2026 to 2036.

  • In May 2026, The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd; Enhertu) for two new indications in adults with HER2-positive early-stage breast cancer, marking the therapy’s first approvals in the early-stage setting. The first approval covers the use of neoadjuvant T-DXd followed by taxane, trastuzumab, and pertuzumab (THP) for patients with stage II or III HER2-positive (IHC 3+ or ISH+) breast cancer. The second approval authorizes adjuvant T-DXd for adults with HER2-positive (IHC 3+ or ISH+) breast cancer who continue to have residual invasive disease after receiving neoadjuvant trastuzumab-based, with or without pertuzumab, and taxane-based treatment.

  • In December 2025, Following the strong clinical results reported in June by AstraZeneca and Daiichi Sankyo for Enhertu in a combination regimen for a specific type of breast cancer, the therapy has now received FDA approval for that indication. The U.S. regulator has approved Enhertu in combination with Roche’s Perjeta as a first-line treatment for patients with unresectable or metastatic HER2-positive breast cancer, as confirmed by an FDA-approved diagnostic test.

  • In December 2025, The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in combination with pertuzumab (Perjeta) as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, as determined by an FDA-approved diagnostic test. Alongside this approval, the agency also cleared the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the HER2 Dual ISH DNA Probe Cocktail as companion diagnostic tools to help identify patients eligible for this therapy, according to a regulatory news release.

  • In June 2025, AstraZeneca and Daiichi Sankyo reported positive results from the Phase III DESTINY-Breast09 trial (NCT04784715) evaluating Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab as a first-line therapy for HER2-positive metastatic breast cancer. The Enhertu-pertuzumab combination showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the standard THP regimen (taxane, trastuzumab, and pertuzumab). Full findings from the study were presented at the 2025 ASCO Annual Meeting.

  • In May 2025, Topline findings from the Phase III DESTINY-Breast11 trial (NCT05113251) revealed that Enhertu (trastuzumab deruxtecan; AstraZeneca and Daiichi Sankyo) followed by standard HER2-targeted therapy significantly improved pathologic complete response (pCR) rates compared to standard chemotherapy in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Investigators noted that these results highlight Enhertu’s potential as an alternative to anthracycline-based regimens for high-risk patients.

  • In February 2025, KN026 combined with docetaxel demonstrated an Objective Response Rate (ORR) of 76.4% in HER2-positive breast cancer. The safety profile of KN026 was manageable, with no treatment-related deaths, and it exhibited a potential advantage in terms of reduced cardiac toxicity.

  • According to the estimates, the total incident population of HER2-positive breast cancer in the seven major markets was nearly 104,000 cases in 2025. The cases in the 7MM are expected to increase during the forecast period, i.e., 2025–2036.

  • The metastatic HER2+ breast cases were highest in the treatment eligible pool for HER2+ breast cancer in the US, accounting for ~14,500 cases.

  • According to the estimates, most cases of HER2-positive breast cancer occur in people between 40 and 60 in the United States, accounting for ~52% of total cases in 2025.

  • Among EU4 and the UK, Germany had the maximum total incident cases of HER2-positive breast cancer, with ~10,800 cases in 2025, while Spain accounted for the least number of cases.

  • In Japan, stage-specific cases of HER2-positive breast cancer were highest in Stage II, accounting for ~6,600 cases in 2025.

  • TUKYSA became the first new molecular entity (NME) to undergo review under Project Orbis, an initiative by the FDA Oncology Center of Excellence (OCE). Project Orbis facilitates the simultaneous submission and review of oncology drugs by multiple international regulatory authorities. This streamlined approach enhances access to innovative treatments for patients on a global scale.

  • Since gaining FDA approval in 2020, TUKYSA has been employed alongside trastuzumab and chemotherapy to combat HER2-positive breast cancer following prior treatments in the metastatic setting. KADCYLA, an ADC, utilizes HERCEPTIN as a guide to delivering chemotherapy directly to HER2-expressing cancer cells.

  • While both are HER2-targeted therapies, they face formidable competition from AstraZeneca and Daiichi Sankyo’s ENHERTU, which outperformed KADCYLA in a head-to-head trial. Following this setback, KADCYLA has been focusing on its use in post-surgical early-stage breast cancer and expanding its reach geographically.

  • In 2025, the total market size of HER2+ MBC in first-line was USD 521 million in the US. The highest revenue was captured by Taxane + Trastuzumab + PERJETA (Pertuzumab) ± Hormone therapies accounting for USD 236 million in 2025.

  • Key Metastatic HER2-positive Breast Cancer Companies: MacroGenics, TerSera Therapeutics, Roche, Chugai, Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

  • Key Metastatic HER2-positive Breast Cancer Therapies: MARGENZA (margetuximab-cmkb), KADCYLA (ado-trastuzumab emtansine), ENHERTU (fam-trastuzumab deruxtecan-nxk), ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others

  • The Metastatic HER2-positive Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HER2-positive Breast Cancer pipeline products will significantly revolutionize the Metastatic HER2-positive Breast Cancer market dynamics.

 

Metastatic HER2-positive Breast Cancer Overview

Metastatic HER2-positive breast cancer refers to breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain, and is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer tends to be more aggressive than other types of breast cancer.

 

To Know in detail about the Metastatic HER2-positive Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HER2-positive Breast Cancer Market Forecast

 

Metastatic HER2-positive Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Metastatic HER2-positive Breast Cancer Epidemiology Segmentation:

The Metastatic HER2-positive Breast Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incidence of Breast Cancer in the 7MM

  • Stage-specific Incidence of HER2-positive Breast Cancer in the 7MM

  • Incidence of HER2-positive Breast Cancer Cases by Hormonal Status in the 7MM

  • Line-wise Treatment-eligible Pool for HER2-positive Breast Cancer in the 7MM

  • Age-specific Incidence of HER2-positive Breast Cancer in the 7MM

  • Incidence of HER2-positive Breast Cancer in the 7MM

 

Download the report to understand which factors are driving Metastatic HER2-positive Breast Cancer epidemiology trends @ Metastatic HER2-positive Breast Cancer Epidemiology Forecast

 

Metastatic HER2-positive Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2-positive Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HER2-positive Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic HER2-positive Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Metastatic HER2-positive Breast Cancer Therapies and Key Companies

  • MARGENZA (margetuximab-cmkb): MacroGenics and TerSera Therapeutics

  • KADCYLA (ado-trastuzumab emtansine): Roche/Chugai

  • ENHERTU (fam-trastuzumab deruxtecan-nxk): Daiichi Sankyo/AstraZeneca

  • KADCYLA (ado-trastuzumab emtansine): Roche/Chugai

  • HERCEPTIN HYLECTA: Roche

  • TUKYSA: Seagen

  • MARGENZA: MacroGenics

  • ARX788: Ambrx

  • Zanidatamab: Zymeworks/Jazz Pharmaceuticals

  • TAS2940: Taiho Oncology

  • GQ1001: GeneQuantum Healthcare

  • Giredestrant: Roche

  • Alpelisib: Criterium, Inc.

  • Tucatinib: Seagen Inc.

  • BL-M07D1: Sichuan Baili Pharma

  • BI-1607: BioInvent International AB

 

Discover more about therapies set to grab major Metastatic HER2-positive Breast Cancer market share @ Metastatic HER2-positive Breast Cancer Treatment Landscape

 

Metastatic HER2-positive Breast Cancer Market Drivers

  • Strong uptake of Daiichi/Astra’s ENHERTU in second and third-line metastatic patients, owing to the unprecedented PFS any therapy in later lines could have ever achieved.

  • Therapies for treating patients whose disease is resistant or refractory to prior HER2 treatment can potentially change the market dynamics in later-line settings.

 

Metastatic HER2-positive Breast Cancer Market Barriers

  • As the current landscape of HER2+ is already packed with old aged blockbuster therapies, companies such as Ambrx BioPharma are developing novel therapies, aiming to target ENHERTU treated patients

  • Despite the treatment with ADCs, around 20–30% of patients progress within 12 months, so there can be a significant market opportunity for therapies targeting these patients.

 

Scope of the Metastatic HER2-positive Breast Cancer Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Metastatic HER2-positive Breast Cancer Companies: MacroGenics, TerSera Therapeutics, Roche, Chugai, Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

  • Key Metastatic HER2-positive Breast Cancer Therapies: MARGENZA (margetuximab-cmkb), KADCYLA (ado-trastuzumab emtansine), ENHERTU (fam-trastuzumab deruxtecan-nxk), ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others

  • Metastatic HER2-positive Breast Cancer Therapeutic Assessment: Metastatic HER2-positive Breast Cancer current marketed and Metastatic HER2-positive Breast Cancer emerging therapies

  • Metastatic HER2-positive Breast Cancer Market Dynamics: Metastatic HER2-positive Breast Cancer market drivers and Metastatic HER2-positive Breast Cancer market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Metastatic HER2-positive Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic HER2-positive Breast Cancer Market Access and Reimbursement

 

To know more about Metastatic HER2-positive Breast Cancer companies working in the treatment market, visit @ Metastatic HER2-positive Breast Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Metastatic HER2-positive Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic HER2-positive Breast Cancer

3. SWOT analysis of Metastatic HER2-positive Breast Cancer

4. Metastatic HER2-positive Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic HER2-positive Breast Cancer Market Overview at a Glance

6. Metastatic HER2-positive Breast Cancer Disease Background and Overview

7. Metastatic HER2-positive Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic HER2-positive Breast Cancer

9. Metastatic HER2-positive Breast Cancer Current Treatment and Medical Practices

10. Metastatic HER2-positive Breast Cancer Unmet Needs

11. Metastatic HER2-positive Breast Cancer Emerging Therapies

12. Metastatic HER2-positive Breast Cancer Market Outlook

13. Country-Wise Metastatic HER2-positive Breast Cancer Market Analysis (2022–2036)

14. Metastatic HER2-positive Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic HER2-positive Breast Cancer Market Drivers

16. Metastatic HER2-positive Breast Cancer Market Barriers

17. Metastatic HER2-positive Breast Cancer Appendix

18. Metastatic HER2-positive Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/